Brokers Set Expectations for FibroGen, Inc.'s Q3 2022 Earnings (NASDAQ:FGEN)
Brokers Set Expectations for FibroGen, Inc.'s Q3 2022 Earnings (NASDAQ:FGEN)
FibroGen, Inc. (NASDAQ:FGEN – Get Rating) – Equities research analysts at Jefferies Financial Group increased their Q3 2022 earnings per share estimates for shares of FibroGen in a research report issued to clients and investors on Tuesday, August 9th. Jefferies Financial Group analyst M. Yee now forecasts that the biopharmaceutical company will earn ($0.84) per share for the quarter, up from their prior estimate of ($0.98). The consensus estimate for FibroGen's current full-year earnings is ($3.24) per share. Jefferies Financial Group also issued estimates for FibroGen's Q4 2022 earnings at ($0.86) EPS, FY2022 earnings at ($3.18) EPS and FY2023 earnings at ($3.36) EPS.
FibroGen，Inc.(納斯達克：FDEN-GET評級)-傑富瑞金融集團的股票研究分析師在8月9日星期二發佈給客户和投資者的一份研究報告中，上調了他們對FibroGen股票2022年第三季度每股收益的預期。傑富瑞金融集團(Jefferies Financial Group)分析師M.Yee現在預測，這家生物製藥公司本季度的每股收益將為0.84美元，高於此前預測的0.98美元。對FibroGen目前全年收益的普遍預期為每股3.24美元。傑富瑞金融集團還發布了對FibroGen 2022財年第四季度每股收益(0.86美元)、2022財年每股收益(3.18美元)和2023財年每股收益(3.36美元)的估計。
Other equities research analysts have also issued reports about the stock. StockNews.com lowered shares of FibroGen from a "buy" rating to a "hold" rating in a research note on Wednesday. The Goldman Sachs Group reduced their price target on FibroGen from $9.00 to $8.00 and set a "sell" rating for the company in a research report on Tuesday, May 24th.
其他股票研究分析師也發佈了有關該股的報告。在週三的一份研究報告中，StockNews.com將FibroGen的股票評級從“買入”下調至“持有”。5月24日，高盛夫婦將FibroGen的目標價從9.00美元下調至8.00美元，並在週二的一份研究報告中為該公司設定了“賣出”評級。
FibroGen Stock Up 3.1 %
FibroGen股價上漲3.1%
FibroGen (NASDAQ:FGEN – Get Rating) last posted its quarterly earnings data on Monday, August 8th. The biopharmaceutical company reported ($0.78) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.94) by $0.16. The business had revenue of $29.81 million during the quarter, compared to the consensus estimate of $36.15 million. FibroGen had a negative return on equity of 100.51% and a negative net margin of 83.64%. FibroGen's quarterly revenue was up 22.3% on a year-over-year basis. During the same period last year, the company earned ($1.45) earnings per share.
FibroGen(納斯達克代碼：FDEN-GET Rating)上一次公佈季度收益數據是在8月8日星期一。這家生物製藥公司公佈了該季度每股收益(EPS)(0.78美元)，比分析師普遍預期的(0.94美元)高出0.16美元。該業務本季度的收入為2981萬美元，而普遍預期為3615萬美元。FibroGen的淨資產回報率為負100.51%，淨利潤率為負83.64%。FibroGen的季度營收同比增長22.3%。去年同期，該公司每股收益為1.45美元。
Institutional Investors Weigh In On FibroGen
機構投資者對FibroGen的看法
A number of large investors have recently added to or reduced their stakes in the business. Point72 Asset Management L.P. grew its stake in FibroGen by 235.9% in the 4th quarter. Point72 Asset Management L.P. now owns 3,732,594 shares of the biopharmaceutical company's stock valued at $52,630,000 after buying an additional 2,621,494 shares during the last quarter. Soleus Capital Management L.P. acquired a new stake in FibroGen during the 4th quarter worth approximately $21,862,000. Federated Hermes Inc. boosted its stake in FibroGen by 84.1% in the 1st quarter. Federated Hermes Inc. now owns 2,395,883 shares of the biopharmaceutical company's stock valued at $28,799,000 after purchasing an additional 1,094,403 shares during the period. First Trust Advisors LP grew its holdings in FibroGen by 24.8% in the 4th quarter. First Trust Advisors LP now owns 5,317,613 shares of the biopharmaceutical company's stock valued at $74,978,000 after buying an additional 1,055,536 shares in the last quarter. Finally, Assenagon Asset Management S.A. increased its position in FibroGen by 333.0% during the 2nd quarter. Assenagon Asset Management S.A. now owns 972,901 shares of the biopharmaceutical company's stock worth $10,274,000 after buying an additional 748,230 shares during the period. Institutional investors own 77.35% of the company's stock.
一些大型投資者最近增持或減持了該公司的股份。72Point72Asset Management L.P.在第四季度增持了235.9%的FibroGen股份。Point72 Asset Management L.P.在上個季度額外購買了2,621,494股後，現在擁有這家生物製藥公司3,732,594股票，價值52,630,000美元。Soleus Capital Management L.P.在第四季度收購了FibroGen的新股份，價值約21,862,000美元。聯合愛馬仕公司在第一季度增持了84.1%的FibroGen股份。聯合愛馬仕公司目前持有這家生物製藥公司2,395,883股股票，價值28,799,000美元，在此期間又購買了1,094,403股。First Trust Advisors LP在第四季度增持了24.8%的FibroGen。First Trust Advisors LP現在擁有這家生物製藥公司5,317,613股股票，價值74,978,000美元，上個季度又購買了1,055,536股。最後，Assenagon Asset Management S.A.在第二季度將其在FibroGen的頭寸增加了333.0%。Assenagon Asset Management S.A.現在持有這家生物製藥公司972,901股票，價值10,274,000美元，在此期間又購買了748,230股票。機構投資者持有該公司77.35%的股份。
FibroGen Company Profile
FibroGen公司簡介
(Get Rating)
(獲取評級)
FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes.
FibroGen，Inc.是一家生物製藥公司，發現、開發和商業化治療嚴重未得到滿足的醫療需求的療法。該公司正在開發一種口服低氧誘導因子Pro羥基酶小分子抑制劑roxadustat，該藥已在美國、歐洲、中國和日本完成了治療慢性腎臟疾病貧血的第三階段臨牀開發，並在中國完成了治療與骨髓增生異常綜合徵相關的貧血的第二/第三階段臨牀開發。
Featured Articles
專題文章
- Get a free copy of the StockNews.com research report on FibroGen (FGEN)
- 2 Important Retail Stock Battles to Watch
- MarketBeat: Week in Review 8/8 – 8/12
- What Is WallStreetBets and What Stocks Are They Targeting?
- Institutions And Analysts Propel Jack In The Box Higher
- Can You Guess Which EV Stock Is Beating Tesla ?
- 免費獲取StockNews.com關於FibroGen的研究報告(Fgen)
- 值得關注的兩場重要的零售股大戰
- MarketBeat：回顧中的一週2012-8-8
- 什麼是WallStreetBets，他們的目標是什麼股票？
- 機構和分析師推動Jack in the Box走高
- 你能猜到哪個電動車股票打敗了特斯拉嗎？
Receive News & Ratings for FibroGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen and related companies with MarketBeat.com's FREE daily email newsletter.
接受FibroGen Daily的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對FibroGen和相關公司的最新新聞和分析師評級的每日簡要摘要。